An update on the use of antihistamines in managing chronic urticaria
Expert Opin Pharmacother. 2024 Apr 23. doi: 10.1080/14656566.2024.2345731. Online ahead of print.ABSTRACTINTRODUCTION: Urticaria, a mast cell-mediated skin disease, manifests as acute or chronic, with the latter divided into spontaneous and inducible types and requires individualized management, including identifying triggers and comorbidities. Antihistamines, particularly the second generation group, form the mainstay of primary treatment plans consisting of dosage adjustments and/or in combination with other treatment modalities depending on underlying disease control.AREAS COVERED: A literature search was conducted usin...
Source: Expert Opinion on Pharmacotherapy - April 24, 2024 Category: Drugs & Pharmacology Authors: Yi-Kui Xiang Jie Shen Fok Indrashis Podder Muhammed Burak Y ücel Defne Özkoca Simon Francis Thomsen Emek Kocat ürk Source Type: research
Novel pharmacotherapeutic avenues for bladder storage dysfunction in men
Expert Opin Pharmacother. 2024 Apr 24:1-10. doi: 10.1080/14656566.2024.2346278. Online ahead of print.ABSTRACTINTRODUCTION: Bladder storage dysfunction is associated with low quality of life in men and remains a challenging field in pharmacotherapy because of low persistence followed by patient-perceived lack of efficacy and adverse effects. The persistent desire for the development of novel pharmacotherapy is evident, leading to numerous research efforts based on its pathophysiology.AREAS COVERED: This review describes the pathophysiology, current pharmacotherapeutic strategies, and emerging novel drugs for male bladder s...
Source: Expert Opinion on Pharmacotherapy - April 23, 2024 Category: Drugs & Pharmacology Authors: Kang Jun Cho Joon Chul Kim Source Type: research
How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
Expert Opin Pharmacother. 2024 Apr 23. doi: 10.1080/14656566.2024.2345734. Online ahead of print.ABSTRACTINTRODUCTION: Tauopathies are a spectrum of clinicopathological neurodegenerative disorders with increased aggregates included in glia and/or neurons of hyperphosphorylated insoluble tau protein, a microtubule-associated protein. Progressive supranuclear palsy (PSP) is an atypical dopaminergic-resistant parkinsonian syndrome, considered as a primary tauopathy with possible alteration of tau isoform ratio, and tau accumulations characterized by 4 R tau species as the main neuropathological lesions.AREAS COVERED: In the p...
Source: Expert Opinion on Pharmacotherapy - April 23, 2024 Category: Drugs & Pharmacology Authors: Madia Lozupone Vittorio Dibello Antonio Daniele Vincenzo Solfrizzi Emanuela Resta Francesco Panza Source Type: research
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy
Expert Opin Pharmacother. 2024 Apr 22. doi: 10.1080/14656566.2024.2346268. Online ahead of print.ABSTRACTINTRODUCTION: Acute kidney injury (AKI) frequently develops in patients receiving cancer therapy and requires a wide differential diagnosis due to possible role of unique cancer and drug-related factors, in addition to common pre- and post-renal causes. Rapid development of new molecular targeted anti-cancer drugs and immunotherapies has opened unprecedented possibilities of treatment at the price of an increased spectrum of renal side effects.AREAS COVERED: The present review aims at providing a state-of-the-art pictur...
Source: Expert Opinion on Pharmacotherapy - April 22, 2024 Category: Drugs & Pharmacology Authors: Emanuele Parodi Maura Rossi Achille Bottiglieri Marco Ladetto Guido Merlotti Vincenzo Cantaluppi Marco Quaglia Source Type: research
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
CONCLUSION: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with a larger number of patients.PMID:38629387 | DOI:10.1080/14656566.2024.2343092 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 17, 2024 Category: Drugs & Pharmacology Authors: Alexia Bikou Foteini Dermiki-Gkana Michail Penteris Theodoros K Constantinides Christos Kontogiorgis Source Type: research
Current and emerging pharmacotherapy for the treatment of gastroparesis
Expert Opin Pharmacother. 2024 Apr 17. doi: 10.1080/14656566.2024.2344646. Online ahead of print.ABSTRACTINTRODUCTION: Gastroparesis is a chronic disorder characterized by decreased gastric emptying and presents with nausea, vomiting, and abdominal pain which impacts patients' quality of life greatly. The treatment modalities available for gastroparesis have been expanding over the past 2 decades. Currently there are multiple options available for gastroparesis albeit with only one FDA approved medication until June of 2021.AREAS COVERED: We review the different treatments available for gastroparesis and discuss the recent...
Source: Expert Opinion on Pharmacotherapy - April 17, 2024 Category: Drugs & Pharmacology Authors: M Ammar Kalas Irene Sarosiek Richard W McCallum Source Type: research
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
CONCLUSION: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with a larger number of patients.PMID:38629387 | DOI:10.1080/14656566.2024.2343092 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 17, 2024 Category: Drugs & Pharmacology Authors: Alexia Bikou Foteini Dermiki-Gkana Michail Penteris Theodoros K Constantinides Christos Kontogiorgis Source Type: research
Current and emerging pharmacotherapy for the treatment of gastroparesis
Expert Opin Pharmacother. 2024 Apr 17. doi: 10.1080/14656566.2024.2344646. Online ahead of print.ABSTRACTINTRODUCTION: Gastroparesis is a chronic disorder characterized by decreased gastric emptying and presents with nausea, vomiting, and abdominal pain which impacts patients' quality of life greatly. The treatment modalities available for gastroparesis have been expanding over the past 2 decades. Currently there are multiple options available for gastroparesis albeit with only one FDA approved medication until June of 2021.AREAS COVERED: We review the different treatments available for gastroparesis and discuss the recent...
Source: Expert Opinion on Pharmacotherapy - April 17, 2024 Category: Drugs & Pharmacology Authors: M Ammar Kalas Irene Sarosiek Richard W McCallum Source Type: research
A systematic review of the effect of semaglutide on Lean Mass: insights from clinical trials
CONCLUSION: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with larger number of patients.PMID:38629387 | DOI:10.1080/14656566.2024.2343092 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 17, 2024 Category: Drugs & Pharmacology Authors: Alexia Bikou Foteini Dermiki-Gkana Michail Penteris Theodoros K Constantinides Christos Kontogiorgis Source Type: research
An update on antifungal resistance in Dermatophytosis
Expert Opin Pharmacother. 2024 Apr 16. doi: 10.1080/14656566.2024.2343079. Online ahead of print.ABSTRACTINTRODUCTION: The reports of resistance to antifungal agents used for treating onychomycosis and other superficial fungal infections are increasing. This rise in antifungal resistance poses a public health challenge that requires attention.AREAS COVERED: This review explores the prevalence of dermatophytes and the current relationship between dermatophyte species, their minimum inhibitory concentrations (MICs) for terbinafine (an allylamine) and itraconazole (an azole), and various mutations prevalent in these species. ...
Source: Expert Opinion on Pharmacotherapy - April 16, 2024 Category: Drugs & Pharmacology Authors: Aditya K Gupta Avantika Mann Shruthi Polla Ravi Tong Wang Source Type: research
Momelotinib in myelofibrosis
Expert Opin Pharmacother. 2024 Apr 16. doi: 10.1080/14656566.2024.2343780. Online ahead of print.ABSTRACTINTRODUCTION: Myelofibrosis (MF) is a hematologic disease characterized by bone marrow fibrosis, cytopenias, splenomegaly, and constitutional symptoms. Recent years have seen the emergence of novel therapeutic agents, notably ruxolitinib and fedratinib, which target the Janus kinases (JAK) pathway. However, their myelosuppressive effect coupled with the persistence, and even worsening anemia remains a significant challenge, leading usually to treatment discontinuation.AREAS COVERED: This review focuses on Momelotinib (M...
Source: Expert Opinion on Pharmacotherapy - April 16, 2024 Category: Drugs & Pharmacology Authors: Antonella Bruzzese Enrica Antonia Martino Caterina Labanca Francesco Mendicino Eugenio Lucia Virginia Olivito Annamaria Zimbo Valentina Fragliasso Antonino Neri Fortunato Morabito Ernesto Vigna Massimo Gentile Source Type: research
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data
Expert Opin Pharmacother. 2024 Apr 15. doi: 10.1080/14656566.2024.2343782. Online ahead of print.ABSTRACTINTRODUCTION: Friedreich ataxia (FRDA) is a rare autosomal recessive disease, marked by loss of coordination as well as impaired neurological, endocrine, orthopedic, and cardiac function. There are many symptomatic medications for FRDA, and many clinical trials have been performed, but only one FDA-approved medication exists.AREAS COVERED: The relative absence of the frataxin protein (FXN) in FRDA causes mitochondrial dysfunction, resulting in clinical manifestations. Currently, the only approved treatment for FRDA is a...
Source: Expert Opinion on Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Katherine Gunther David R Lynch Source Type: research
A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy
CONCLUSION: Ganaxolone presents itself as a viable therapeutic option for refractory epilepsy, showing efficacy in reducing seizure frequency and exhibited a favorable safety profile.PROSPERO REGISTRATION NUMBER: CRD42023434883.PMID:38606458 | DOI:10.1080/14656566.2024.2342413 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 12, 2024 Category: Drugs & Pharmacology Authors: Parvej Khan Sparsh Saini Shadan Hussain Haya Majid Sparsh Gupta Nidhi Agarwal Source Type: research
Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma
Expert Opin Pharmacother. 2024 Apr 12. doi: 10.1080/14656566.2024.2342403. Online ahead of print.ABSTRACTINTRODUCTION: Increasing evidence from preclinical and clinical studies suggests the role of vascular endothelial growth factor (VEGF) signaling in melanoma progression, response to therapy, and overall survival. Moreover, the discovery of the potential involvement of the VEGF pathway in resistance to immunotherapy has led to new clinical trials with VEGFR inhibitors.AREAS COVERED: We have reviewed recent literature, mainly published within the last 5 years, on VEGFR-targeted treatments for advanced melanoma, including ...
Source: Expert Opinion on Pharmacotherapy - April 12, 2024 Category: Drugs & Pharmacology Authors: Pawe ł Sobczuk Micha ł Cholewiński Piotr Rutkowski Source Type: research
A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy
CONCLUSION: Ganaxolone presents itself as a viable therapeutic option for refractory epilepsy, showing efficacy in reducing seizure frequency and exhibited a favorable safety profile.PROSPERO REGISTRATION NUMBER: CRD42023434883.PMID:38606458 | DOI:10.1080/14656566.2024.2342413 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - April 12, 2024 Category: Drugs & Pharmacology Authors: Parvej Khan Sparsh Saini Shadan Hussain Haya Majid Sparsh Gupta Nidhi Agarwal Source Type: research
